Nasdaq · Healthcare
ASSEMBLY BIOSCIENCES, INC. (ASMB)
As-reported financials and recent SEC filings for ASSEMBLY BIOSCIENCES, INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$72.3M
Net income
$-6.1M
Net margin
-8.5%
Diluted EPS
$-0.55
ROE
-3.0%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $72.3M | $28.5M | $7.2M | $0 | $6.3M |
| Gross profit | — | — | — | — | — |
| Operating income | $-12.1M | $-45.4M | $-64.6M | $-94.1M | $-132.7M |
| Net income | $-6.1M | $-40.2M | $-61.2M | $-93.1M | $-129.9M |
| Diluted EPS | $-0.55 | $-6.69 | $-13.38 | $-23.08 | $-33.00 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-18
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →Largest Healthcare peers
Go deeper on ASMB
Search ASSEMBLY BIOSCIENCES, INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.